Ventyx Biosciences Statistics
Share Statistics
Ventyx Biosciences has 70.71M shares outstanding. The number of shares has increased by 19.68% in one year.
| Shares Outstanding | 70.71M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.24% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 53.34M |
| Failed to Deliver (FTD) Shares | 132 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 8.14M, so 11.51% of the outstanding shares have been sold short.
| Short Interest | 8.14M |
| Short % of Shares Out | 11.51% |
| Short % of Float | 15.11% |
| Short Ratio (days to cover) | 9.91 |
Valuation Ratios
The PE ratio is -0.75 and the forward PE ratio is -0.99.
| PE Ratio | -0.75 |
| Forward PE | -0.99 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.59 |
| P/FCF Ratio | -0.87 |
| PEG Ratio | n/a |
Enterprise Valuation
Ventyx Biosciences Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 11.87, with a Debt / Equity ratio of 0.
| Current Ratio | 11.87 |
| Quick Ratio | 11.87 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.79% and return on capital (ROIC) is -81.11%.
| Return on Equity (ROE) | -0.79% |
| Return on Assets (ROA) | -0.69% |
| Return on Capital (ROIC) | -81.11% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.57M |
| Employee Count | 75 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 0.89% in the last 52 weeks. The beta is 0.37, so Ventyx Biosciences 's price volatility has been higher than the market average.
| Beta | 0.37 |
| 52-Week Price Change | 0.89% |
| 50-Day Moving Average | 2.27 |
| 200-Day Moving Average | 3.45 |
| Relative Strength Index (RSI) | 50.68 |
| Average Volume (20 Days) | 1.52M |
Income Statement
In the last 12 months, Ventyx Biosciences had revenue of $0 and earned -$192.96M in profits. Earnings per share was $-3.3.
| Revenue | 0 |
| Gross Profit | -941.00K |
| Operating Income | -207.99M |
| Net Income | -192.96M |
| EBITDA | -207.99M |
| EBIT | - |
| Earnings Per Share (EPS) | -3.3 |
Balance Sheet
The company has $51.58M in cash and $12.51M in debt, giving a net cash position of $39.07M.
| Cash & Cash Equivalents | 51.58M |
| Total Debt | 12.51M |
| Net Cash | 39.07M |
| Retained Earnings | -419.19M |
| Total Assets | 301.10M |
| Working Capital | 277.11M |
Cash Flow
In the last 12 months, operating cash flow was -$166.52M and capital expenditures -$514.00K, giving a free cash flow of -$167.04M.
| Operating Cash Flow | -166.52M |
| Capital Expenditures | -514.00K |
| Free Cash Flow | -167.04M |
| FCF Per Share | -2.85 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
VTYX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -145.37% |
| FCF Yield | -103.83% |
Analyst Forecast
The average price target for VTYX is $9, which is 296.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $9 |
| Price Target Difference | 296.5% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 1.6 |
| Piotroski F-Score | 2 |